Document Detail

Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression.
MedLine Citation:
PMID:  23013138     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Multimarker quantitative real-time polymerase chain reaction (qRT-PCR) represents an effective method for detecting circulating tumour cells in the peripheral blood of patients with melanoma.
OBJECTIVES: To investigate whether the phenotype of circulating melanoma cells represents a useful indicator of disease stage, recurrence and treatment efficacy.
METHODS:   Peripheral blood was collected from 230 patients with melanoma and 152 healthy controls over a period of 3years and 9months. Clinical data and blood samples were collected from patients with primary melanoma (early stages, 0-II, n=154) and metastatic melanoma (late stages, III-IV, n=76). Each specimen was examined by qRT-PCR analysis for the expression of five markers: MLANA, ABCB5, TGFβ2, PAX3d and MCAM.
RESULTS:  In total, 212 of the patients with melanoma (92%) expressed markers in their peripheral blood. Two markers, MLANA and ABCB5, had the greatest prognostic value, and were identified as statistically significant among patients who experienced disease recurrence within our study period, being expressed in 45% (MLANA) and 49% (ABCB5) of patients with recurrence (P=0·001 and P=0·031, respectively). For patients administered nonsurgical treatments, MCAM expression correlated with poor treatment outcome.
CONCLUSIONS: Circulating tumour cells were detectable at all stages of disease and long after surgical treatment, even when patients were considered disease free. Specifically, expression of ABCB5 and MLANA had significant prognostic value in inferring disease recurrence, while MCAM expression was associated with poor patient outcome after treatment, confirming multimarker qRT-PCR as a potential technique for monitoring disease status.
A L Reid; M Millward; R Pearce; M Lee; M H Frank; A Ireland; L Monshizadeh; T Rai; P Heenan; S Medic; P Kumarasinghe; M Ziman
Related Documents :
15090278 - Pulsed-dose rate brachytherapy with concomitant chemotherapy and interstitial hyperther...
24040098 - Sil-tal1 rearrangement is related with poor outcome: a study from a chinese institution.
8244808 - Treatment results of high dose rate brachytherapy in patients with carcinoma of the cer...
14970798 - Ocular motility disturbances after episcleral plaque brachytherapy for uveal melanoma.
21858608 - Treatment of recurrent diffuse intrinsic pontine glioma: the md anderson cancer center ...
15860868 - Catalytic subunit of human telomerase reverse transcriptase is an independent predictor...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2012-11-15
Journal Detail:
Title:  The British journal of dermatology     Volume:  168     ISSN:  1365-2133     ISO Abbreviation:  Br. J. Dermatol.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-02     Completed Date:  2013-06-07     Revised Date:  2014-09-09    
Medline Journal Info:
Nlm Unique ID:  0004041     Medline TA:  Br J Dermatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  85-92     Citation Subset:  IM    
Copyright Information:
© 2012 The Authors. BJD © 2012 British Association of Dermatologists.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Case-Control Studies
Melanoma / blood,  pathology*,  therapy
Middle Aged
Neoplasm Recurrence, Local / pathology*
Neoplastic Cells, Circulating / pathology*
Real-Time Polymerase Chain Reaction
Skin Neoplasms / blood,  pathology*,  therapy
Treatment Outcome
Tumor Burden
Tumor Markers, Biological / blood*
Young Adult
Grant Support
1R01CA138231/CA/NCI NIH HHS; 1R01CA158467/CA/NCI NIH HHS; 2P50CA093683/CA/NCI NIH HHS; 5R01CA113796/CA/NCI NIH HHS; P50 CA093683/CA/NCI NIH HHS; R01 CA113796/CA/NCI NIH HHS; R01 CA138231/CA/NCI NIH HHS; R01 CA158467/CA/NCI NIH HHS
Reg. No./Substance:
0/Tumor Markers, Biological
Comment In:
Br J Dermatol. 2013 Jan;168(1):3   [PMID:  23278557 ]
Br J Dermatol. 2014 Jul;171(1):190-1   [PMID:  24397844 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  HIV prevalence and incidence among women at higher risk of infection in Addis Ababa, Ethiopia.
Next Document:  Hepatic resection for bilateral hepatolithiasis: a 20-year experience.